The aetiology of metabolic disturbances in schizophrenia - drugs, genes and environment by Reynolds, Gavin P.
The aetiology of metabolic disturbances in schizophrenia - 
drugs, genes and environment
REYNOLDS, Gavin P. <http://orcid.org/0000-0001-9026-7726>
Available from Sheffield Hallam University Research Archive (SHURA) at:
http://shura.shu.ac.uk/29124/
This document is the author deposited version.  You are advised to consult the 
publisher's version if you wish to cite from it.
Published version
REYNOLDS, Gavin P. (2021). The aetiology of metabolic disturbances in 
schizophrenia - drugs, genes and environment. Int J Neuropsychopharmacol. 
Copyright and re-use policy
See http://shura.shu.ac.uk/information.html




Received: May 25, 2021; Accepted: July 10, 2021
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.
org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is 
properly cited.
© The Author(s) 2021. Published by Oxford University Press on behalf of CINP.
Letter to Editor
The Etiology of Metabolic Disturbances in 
Schizophrenia: Drugs, Genes, and Environment
Gavin P. Reynolds PhD
Biomolecular Sciences Research Centre, Sheffield Hallam University, Howard Street, Sheffield S1 1WB, UK (Dr 
Reynolds).
Correspondence: Gavin P. Reynolds, PhD, Biomolecular Sciences Research Centre, Sheffield Hallam University, Howard Street, Sheffield S1 1WB, UK 
(gavin.reynolds@shu.ac.uk).
Mizuki et al. (2021) have provided an extensive analysis of the 
relationship between type 2 diabetes (T2D) and schizophrenia in 
which they have focused on a possible commonality of genetic 
risk as well as reviewing in depth some molecular mechanisms 
that may underlie the relationship between these 2 diseases. 
There is much to elucidate in this important yet complex topic, 
which, as these authors acknowledge, remains far from fully 
understood. Some of the points they raise do, however, deserve 
further debate. Although this discussion could be more exten-
sive, I wish to address just 3 questions that emerge from this 
interesting article.
How strong is the link between schizophrenia and T2D? It is 
well established that there is an elevated incidence of diabetes 
in people with schizophrenia. The extent of this increased in-
cidence depends strongly on the particular drugs being taken 
(Koro et al., 2002), indicating that antipsychotic medication, par-
ticularly with drugs that also induce weight gain, makes a sub-
stantial contribution to this relationship. Other consequences 
or correlates of schizophrenia, such as higher prevalence of 
smoking, less exercise, and poor diet, may also contribute to 
T2D risk, leading to the suggestion from Mizuki et al. (2021) that 
“schizophrenia itself is a risk for increased onset of diabetes.” 
More difficult is determining whether there is an inherent as-
sociation between schizophrenia and T2D independent of the 
consequences of psychotic symptoms and their treatment. The 
main approach is to search for T2D risk factors in early-stage, 
drug-naïve schizophrenia patients.
Unsurprisingly, there is really no evidence for an increased 
prevalence of T2D in such patients, given that it typically takes 
many years to develop. Several groups fail to identify any sig-
nificant metabolic abnormalities at this early stage of psych-
otic illness, although some reports cited by Mizuki et al. (2021), 
including the meta-analysis of Pillinger et al. (2017), have iden-
tified increases in markers of glucose intolerance and insulin 
resistance. However, these findings still question whether the 
effect is truly trait, rather than state, related. For example, a 
study included in Pillinger et al. (2017) and showing an unusually 
large elevation in fasting glucose is that of Zhang et al. (2015); 
their participants had a reported duration of untreated illness 
of 24 months, during which time the schizophrenia-related be-
haviors mentioned above may well have contributed to the de-
velopment of metabolic disturbances. Incidentally, the findings 
of Zhang et al. (2015) contrast profoundly with an earlier report 
from the same group in which no elevation compared with con-
trols was found (Chen et  al., 2013); this inconsistency reflects 
a substantial difference in fasting glucose not between the pa-
tient groups but between the controls! While Mizuki et al. (2021) 
identify other evidence for subtle differences in indicators of 
relative glucose intolerance or insulin resistance in first episode 
patients, it is important to bear in mind that these measures are 
not inevitable precursors of T2D.
Mizuki et  al. (2021) hypothesize that common genetic fac-
tors may underlie the co-existence of T2D and schizophrenia. 
How strong is the evidence for genetic commonality? These au-
thors identified several candidate genes that overlap between 
the 2 disorders. However, given the fact that most case-control 
candidate gene studies are not replicated by genome-wide as-
sociation studies or of value in identifying genuine associations 
with disease, as has been demonstrated for schizophrenia 
(Johnson et al., 2017), it is perhaps unwise to use candidate gene 
findings to search for genetic commonalities. Perhaps the most 
useful study addressing genetic overlap between schizophrenia 
and T2D is in the very recent report from Perry et al. (2021) using 
genome-wide association studies data from very large cohorts 
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of people with schizophrenia or various cardiometabolic traits. 
These authors show clearly that there is no genetic common-
ality between schizophrenia and T2D. However, after restricting 
their analysis to inflammation-associated markers, they found 
that genetic factors for insulin resistance (but not T2D) were also 
associated with schizophrenia, suggesting that inflammation 
was an etiological factor common to both schizophrenia and 
insulin resistance. This finding is consistent with one of the hy-
pothesized mechanisms discussed by Mizuki et al. (2021).
Are there other factors that may contribute to the relationship 
between schizophrenia and T2D? In addition to the various behav-
ioral risk factors for diabetes seen in people with schizophrenia, 
there are several environmental etiological risks common to both 
schizophrenia and T2D and that have not been considered by 
Mizuki et al. (2021). We have previously pointed out how social 
and economic deprivation, urbanization, migrant background, 
and poor parental care and childhood trauma are risk factors for 
both disorders (Reynolds and McGowan, 2017). A potential feature 
of all these risks is chronic stress; this is associated with dysfunc-
tion of the hypothalamic-pituitary-adrenal axis, which can result 
in, and be further affected by, inflammation (Russell et al., 2018).
There has been little attempt to explore the complex relation-
ships between schizophrenia, metabolic disturbances, and these 
environmental risk factors. However, 1 environmental factor has 
been investigated in terms of the overlap between schizophrenia 
and metabolic dysfunction. The experience of childhood trauma 
in people with first-episode schizophrenia is associated with in-
creased insulin (and the related c-peptide) (Tosato et al., 2020), pro-
viding a possible indication of insulin resistance. Thus, for some 
people with schizophrenia, their disease may derive from early en-
vironmental risk interacting with genetic factors associated with 
inflammation, a process that may also result in metabolic dysfunc-
tion. Of course, as Mizuki et al. (2021) emphasize, schizophrenia is a 
heterogeneous disorder in both etiology and phenomenology, and 
this describes only 1 of multiple mechanisms. Finally, we must not 
let this focus on the inherent relationship between schizophrenia 
and metabolic disturbances distract us from the severe effects on 
body weight and consequent metabolic syndrome that can result 
from several of the drugs used for the treatment of psychosis.
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